AxoGen (NASDAQ: AXGN) reported Q2 EPS of $0.12, $0.06 better than the analyst estimate of $0.06. Revenue for the quarter came in at $56.66 million versus the consensus estimate of $52.66 million.

GUIDANCE:

AxoGen sees FY2025 revenue of $219 million, versus the consensus of $216.18 million.

For earnings history and earnings-related data on AxoGen (AXGN) click here.